Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francois Ghiringhelli

Showing results (41-50 of 95) with videos related to

Pageof 10
Sort By:
Scientific Reports|December 14, 2021
Using a convolutional neural network for classification of squamous and non-squamous non-small cell lung cancer based on diagnostic histopathology HES imagesAnne Laure Le Page, Elise Ballot, Caroline Truntzer, et al.
Journal of Cancer Research and Clinical Oncology|July 6, 2019
Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II studyFrancois Ghiringhelli, Julie Vincent, Leila Bengrine, et al.
Anticancer Research|July 27, 2022
Metronomic Cyclophosphamide With Cisplatin and Bevacizumab for Refractory Anaplastic Ependymoma: A Retrospective StudyXavier Choderlos DE Laclos, Didier Frappaz, Guido Ahle, et al.
ESMO Open|June 27, 2018
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancerJean-David Fumet, Nicolas Isambert, Alice Hervieu, et al.
BMC Cancer|May 18, 2021
FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancerAntoine Adenis, Thibault Mazard, Julien Fraisse, et al.
ESMO Open|March 3, 2023
Corrigendum to "Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer": [ESMO Open 3 (2018) e000375]Jean-David Fumet, Nicolas Isambert, Alice Hervieu, et al.
Journal for Immunotherapy of Cancer|November 21, 2018
RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancerFanny Ledys, Quentin Klopfenstein, Caroline Truntzer, et al.
Journal for Immunotherapy of Cancer|March 12, 2022
MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancerJulie Lecuelle, Laure Favier, Cléa Fraisse, et al.
Anticancer Research|May 29, 2017
Antibiotic Use Does Not Appear to Influence Response to NivolumabCoureche Kaderbhai, Corentin Richard, Jean David Fumet, et al.
JTO Clinical and Research Reports|December 24, 2024
Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLCChristian Rolfo, Laurent Greillier, Remi Veillon, et al.
Pageof 10

Showing results (41-50 of 95) with videos related to

Sort By:
Pageof 10
Scientific Reports|December 14, 2021
Using a convolutional neural network for classification of squamous and non-squamous non-small cell lung cancer based on diagnostic histopathology HES imagesAnne Laure Le Page, Elise Ballot, Caroline Truntzer, et al.
Journal of Cancer Research and Clinical Oncology|July 6, 2019
Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II studyFrancois Ghiringhelli, Julie Vincent, Leila Bengrine, et al.
Anticancer Research|July 27, 2022
Metronomic Cyclophosphamide With Cisplatin and Bevacizumab for Refractory Anaplastic Ependymoma: A Retrospective StudyXavier Choderlos DE Laclos, Didier Frappaz, Guido Ahle, et al.
ESMO Open|June 27, 2018
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancerJean-David Fumet, Nicolas Isambert, Alice Hervieu, et al.
BMC Cancer|May 18, 2021
FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancerAntoine Adenis, Thibault Mazard, Julien Fraisse, et al.
ESMO Open|March 3, 2023
Corrigendum to "Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer": [ESMO Open 3 (2018) e000375]Jean-David Fumet, Nicolas Isambert, Alice Hervieu, et al.
Journal for Immunotherapy of Cancer|November 21, 2018
RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancerFanny Ledys, Quentin Klopfenstein, Caroline Truntzer, et al.
Journal for Immunotherapy of Cancer|March 12, 2022
MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancerJulie Lecuelle, Laure Favier, Cléa Fraisse, et al.
Anticancer Research|May 29, 2017
Antibiotic Use Does Not Appear to Influence Response to NivolumabCoureche Kaderbhai, Corentin Richard, Jean David Fumet, et al.
JTO Clinical and Research Reports|December 24, 2024
Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLCChristian Rolfo, Laurent Greillier, Remi Veillon, et al.
Pageof 10